iXCells Biotechnologies and Rosebud Biosciences have announced a partnership to expand the use of organoid-based models for rare diseases, integrating Rosebud’s 3D human tissue expertise into iXCells’ existing iPSC solutions. The collaboration aims to enhance predictive modeling for drug safety and translational decision-making in complex disease contexts.

Through the partnership, iXCells will combine its iPSCore platform with Rosebud’s organoid generation and characterization capabilities. The integrated workflow provides access to complex 3D human tissue systems that more accurately reflect organ-level biology and therapeutic response. The collaboration is designed to generate scalable, reproducible human tissue data to support drug discovery, toxicity evaluation and translational research.

The expanded platform responds to growing demand for human-relevant and physiologically representative models that improve the predictability of preclinical studies. Organoids are particularly valuable for assessing tissue-specific drug responses and toxicity, offering a consistent, scalable and reproducible system for screening, multi-omics profiling and mechanism-of-action studies.

Steve Smith, chief executive officer of iXCells Biotechnologies, said: “Our focus has always been on anticipating what our partners will need next, and Rosebud brings impressive depth in organoid science that aligns perfectly with that vision. This collaboration enhances our end-to-end platform and expands our ability to deliver next-generation models that reflect human biology with greater depth and accuracy. In areas such as rare diseases, where predicting human-specific safety and response earlier can significantly impact development timelines and patient outcomes, these integrated systems provide critical insight. This partnership reflects the strategic direction we are taking as iXCells scales its platform to support more complex, translationally focused programs for our partners.”

Kitch Wilson, chief executive officer and co-founder of Rosebud Biosciences, added: “Our partnership with iXCells allows us to make advanced organoid systems more accessible to researchers who need models that better represent human biology. By combining our complementary strengths, we can support deeper exploration of disease biology and help drive the next generation of therapeutic discovery.”

The combined iXCells–Rosebud workflow leverages AI-driven organoid platforms alongside scalable, modular iPSC models, providing researchers with more physiologically relevant systems for drug development. The integrated solution aims to support translational decision-making in rare diseases and other conditions where human-specific responses are critical.

This collaboration reflects broader trends in cell and gene therapy and preclinical research, where patient-relevant, human-based models are increasingly required to de-risk development and accelerate timelines. By combining organoid and iPSC technologies, the partnership aims to offer a more complete view of disease mechanisms and drug safety, addressing limitations of traditional 2D cell culture or animal models.